Simponi FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved April 24, 2009)
Brand name: Simponi
Generic name: golimumab
Dosage form: Injection
Company: Johnson & Johnson Innovative Medicine
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis
Simponi (golimumab) is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with:
- Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate
- Active psoriatic arthritis (PsA) alone, or in combination with methotrexate
- Active ankylosing spondylitis (AS)
- Moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy
- inducing and maintaining clinical response
- improving endoscopic appearance of the mucosa during induction
- inducing clinical remission
- achieving and sustaining clinical remission in induction responders
Development timeline for Simponi
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.